Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Has announcements × exemestane × Clear all

Phase

Status

Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 1

Interventions

pembrolizumab 28 Carboplatin 19 Cisplatin 18 Paclitaxel 17 Pemetrexed 13 Nivolumab 13 Dexamethasone 13 Ipilimumab 12 Gemcitabine 10 Fluorouracil 9 Cyclophosphamide 9 atezolizumab 8 Trastuzumab 8 Cytarabine 8 Docetaxel 7 zanubrutinib 6 daratumumab 6 Rituximab 6 Lenalidomide 6 Doxorubicin 6 Daunorubicin 6 Capecitabine 6 nilotinib 5 fludarabine 5 Sunitinib 5 Prednisone 5 Bevacizumab 5 130-nm albumin-bound paclitaxel 5 venetoclax 4 trastuzumab deruxtecan 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03778931 2025-09-15

EMERALD

Stemline Therapeutics, Inc.

Phase 3 Completed

478 enrolled 16 charts 1 FDA

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡